Company news
Oculis Holding Ag (NASDAQ:OCS) news
Oculis Holding Ag news releases on 6ix. Latest, Oct 7, 2026: Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology…
Press releases & updates
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
October 6, 2026
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
October 6, 2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
October 1, 2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors
September 30, 2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors
September 29, 2026
Oculis Announces Resignation of Lionel Carnot from Board of Directors
September 29, 2026
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
August 24, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis Position as an Emerging Leading Neuro-Ophthalmology Company
August 11, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
August 10, 2026
Oculis Reports Q2 2026 Financial Results and Provides Company Update
August 6, 2026
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
August 2, 2026
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
July 1, 2026
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
June 11, 2026
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
June 8, 2026
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
June 7, 2026
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
May 28, 2026
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
May 14, 2026
Oculis Reports Q1 2026 Financial Results and Provides Company Update
May 10, 2026
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
May 7, 2026
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
May 5, 2026
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 19, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 30, 2026
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
March 15, 2026
Oculis to Participate in Upcoming Investor Conferences
March 4, 2026
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
March 3, 2026
Oculis Appoints Katie Kazem as Chief Legal Officer
February 16, 2026
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
January 7, 2026
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
January 6, 2026
Oculis Reports Q3 2025 Financial Results and Provides Company Update
November 9, 2025
Oculis to Participate in Upcoming November Investor Conferences
November 4, 2025
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
October 29, 2025
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
October 13, 2025
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
October 5, 2025
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
September 21, 2025
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
September 3, 2025
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
August 31, 2025
Oculis to Participate in Upcoming September Investor Conferences
August 27, 2025
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
August 24, 2025
Oculis Reports Q2 2025 Financial Results and Provides Company Update
August 20, 2025
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
August 11, 2025
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 11, 2025
Oculis Upsized Loan Facility to Access up to CHF 100 million
July 31, 2025
Oculis Publishes Results of 2025 Annual General Meeting
June 4, 2025
Oculis to Participate in Upcoming June Investor Conferences
June 2, 2025
Oculis Publishes Invitation to the Annual General Meeting
May 8, 2025
Oculis Reports Q1 Financial Results and Provides Company Update
May 7, 2025
Oculis Reports Q1 2025 Financial Results and Provides Company Update
May 7, 2025
Oculis to Present at Upcoming May Investor Conferences
May 6, 2025
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
April 30, 2025
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
April 30, 2025